



**For immediate release:**

## **mtm laboratories Extends Series C Financing Round by EUR 7 Million bringing total to EUR 39 Million (USD 57 Million)**

**Heidelberg, Germany; October 5, 2009-** mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing *in vitro* diagnostics for cervical cancer early detection and diagnosis, today announced the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company's last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in equity.

This completed Series C financing was led by a new investor to mtm laboratories, Gilde Healthcare Partners from Utrecht, The Netherlands, with a consortium which includes HBM BioVentures, Ltd., HBM BioCapital Invest, Ltd., LBBW Venture Capital GmbH, and mtm and Friends. At the same time, Arthur Franken from Gilde Healthcare Partners will join as a new member of the Supervisory Board.

Bob Silverman, Chief Executive Officer of mtm laboratories, commented: "This additional tranche will put mtm in a more favourable position to further leverage the clinical and commercial development of additional product lines. We would also like to welcome Arthur Franken to our Supervisory Board - we feel that mtm will benefit extensively from his experience and commitment."

Arthur Franken, Partner of Gilde Healthcare Partners, added: "We are delighted to support a very talented and experienced team, and invest prior to a major value inflection point. The products have the potential to be truly differentiating in providing clinically relevant and actionable results in the screening and early diagnosis of cervical cancer."

mtm plans to use the proceeds of this financing to expand its clinical development activities and to bolster its commercialization efforts, specifically on the Company's p16<sup>INK4a</sup> based CINtec® and Cervatec™ IVD products.

The basis of mtm's IVD products, the proprietary p16<sup>INK4a</sup> biomarker, is strongly over-expressed in pre-cancerous and cancerous cells of the cervix. Screening and diagnostic tools based on this biomarker are developed to improve the accuracy and efficiency for the screening and early diagnosis of cervical cancer. mtm's CINtec® *in vitro* diagnostic products focus on the detection of p16<sup>INK4a</sup> over-expression in biopsies (CINtec® Histology) and cervical cytology specimens (CINtec® Cytology).

**mtm laboratories AG** is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: [www.mtmlabs.com](http://www.mtmlabs.com).

**Gilde Healthcare Partners** is a European venture capital firm with more than EUR 275 million under management. Gilde Healthcare Partners is headquartered in Utrecht, the Netherlands with representatives in London and Madrid. Gilde is a successful builder of healthcare businesses across Europe. By investing in companies with clear, achievable business models, Gilde has used its financial resources and network to create significant value for both its investors and entrepreneurs partners it backs. For a full list of Gilde portfolio companies please visit [www.gildehealthcare.nl](http://www.gildehealthcare.nl).

<b>Further Information:</b>	
Bob Silverman CEO mtm laboratories AG t: +1 508-366-8334 e: <a href="mailto:contact@mtmlabs.com">contact@mtmlabs.com</a>	Dr. Douglas Pretsell Account Director, Munich Bureau Chief College Hill t : +49 (0)89 57 00 18 06 e: <a href="mailto:douglas.pretsell@collegehill.com">douglas.pretsell@collegehill.com</a>